Theriva Biologics
Clinical-stage immuno-oncology company developing systemically deliverable oncolytic adenovirus therapeutics and complementary orally delivered enzyme programs. Development priorities include engineering tumor-selective oncolytic viruses with stroma-degrading payloads, strategies to enable repeat systemic dosing, clinical development across early and late-phase trials in solid tumors and ocular indications, and oral enzyme programs aimed at protecting the gut microbiome in patients receiving IV beta-lactam antibiotics.
Industries
Nr. of Employees
small (1-50)
Theriva Biologics
Patents
Products
Systemic oncolytic adenovirus candidate (tumor-selective, stroma-degrading)
Intravenously and intravitreally deliverable adenoviral therapeutic engineered for tumor-selective replication and expression of a stroma-degrading enzyme to improve tumor access and immune activation; evaluated across multiple clinical trials in solid tumors and ocular indications.
Albumin-shielded oncolytic virus variants (preclinical)
Next-generation oncolytic virus constructs incorporating albumin-based surface modifications intended to reduce neutralization by circulating antibodies and enable repeat systemic dosing; discovery and preclinical evaluation ongoing.
Oral beta-lactamase enzyme for GI protection (clinical evaluation)
Orally administered beta-lactamase designed to degrade certain intravenously administered beta-lactam antibiotics within the gastrointestinal tract to prevent microbiome damage and reduce complications such as opportunistic overgrowth and graft-versus-host disease in transplant recipients.
Recombinant oral intestinal alkaline phosphatase (cGMP)
Recombinant intestinal alkaline phosphatase produced under cGMP intended to provide local gastrointestinal and potential systemic activity for treatment of GI and related conditions; program in development.
VCN-01
An investigational oncolytic adenovirus therapy developed by Theriva Biologics for the treatment of patients with serious or life-threatening cancers.
SYN-020
Oral recombinant bovine intestinal alkaline phosphatase for potential indications including NAFLD/NASH, celiac, and radiation enteritis.
Systemic oncolytic adenovirus candidate (tumor-selective, stroma-degrading)
Intravenously and intravitreally deliverable adenoviral therapeutic engineered for tumor-selective replication and expression of a stroma-degrading enzyme to improve tumor access and immune activation; evaluated across multiple clinical trials in solid tumors and ocular indications.
Albumin-shielded oncolytic virus variants (preclinical)
Next-generation oncolytic virus constructs incorporating albumin-based surface modifications intended to reduce neutralization by circulating antibodies and enable repeat systemic dosing; discovery and preclinical evaluation ongoing.
Oral beta-lactamase enzyme for GI protection (clinical evaluation)
Orally administered beta-lactamase designed to degrade certain intravenously administered beta-lactam antibiotics within the gastrointestinal tract to prevent microbiome damage and reduce complications such as opportunistic overgrowth and graft-versus-host disease in transplant recipients.
Recombinant oral intestinal alkaline phosphatase (cGMP)
Recombinant intestinal alkaline phosphatase produced under cGMP intended to provide local gastrointestinal and potential systemic activity for treatment of GI and related conditions; program in development.
VCN-01
An investigational oncolytic adenovirus therapy developed by Theriva Biologics for the treatment of patients with serious or life-threatening cancers.
SYN-020
Oral recombinant bovine intestinal alkaline phosphatase for potential indications including NAFLD/NASH, celiac, and radiation enteritis.
Services
Medical-team coordinated review and case-by-case facilitation of individual patient access to investigational oncolytic and enzyme therapies, including documentation, informed consent and adverse event reporting.
Medical-team coordinated review and case-by-case facilitation of individual patient access to investigational oncolytic and enzyme therapies, including documentation, informed consent and adverse event reporting.
Expertise Areas
- Oncolytic virotherapy development
- Clinical trial design and execution (Phase 1–3) and dosing-feasibility studies
- Translational biomarker and omics analyses
- cGMP biologics manufacturing and scale-up
Key Technologies
- Oncolytic adenoviral vectors
- Encoded stroma-degrading enzyme payloads
- Surface modification strategies for immune evasion (albumin-shielding)
- Intravenous and intravitreal delivery methods
News & Updates
Dosing of the first patient in a Phase 2a proof-of-concept study evaluating increased-frequency dosing of the oncolytic adenovirus candidate in combination with gemcitabine/nab-paclitaxel in newly diagnosed metastatic pancreatic cancer.
Spanish national regulator authorized initiation of a Phase 2a single-center trial to evaluate increased-frequency dosing of the oncolytic adenovirus candidate in combination with standard-of-care chemotherapy to inform a potential pivotal Phase 3 dosing regimen.
Poster presentation of tumor response, biomarker and subgroup analyses from the randomized Phase 2b trial indicating an immune-mediated mode of action and improved outcomes in treated patients.
Peer-reviewed publication reporting Phase 1 safety and translational results supporting stroma-degrading and immune-enhancing modes-of-action when the oncolytic adenovirus candidate was administered prior to immune checkpoint inhibition.
Corporate update including regulatory alignment with the FDA on proposed Phase 3 design, presentation of VIRAGE data at AACR, compassionate use dosing in retinoblastoma and financial results through March 31, 2026.
Peer-reviewed publications and conference presentations reporting Phase I and translational results for systemically administered oncolytic adenovirus candidates and related preclinical studies.
Dosing of the first patient in a Phase 2a proof-of-concept study evaluating increased-frequency dosing of the oncolytic adenovirus candidate in combination with gemcitabine/nab-paclitaxel in newly diagnosed metastatic pancreatic cancer.
Spanish national regulator authorized initiation of a Phase 2a single-center trial to evaluate increased-frequency dosing of the oncolytic adenovirus candidate in combination with standard-of-care chemotherapy to inform a potential pivotal Phase 3 dosing regimen.
Poster presentation of tumor response, biomarker and subgroup analyses from the randomized Phase 2b trial indicating an immune-mediated mode of action and improved outcomes in treated patients.
Peer-reviewed publication reporting Phase 1 safety and translational results supporting stroma-degrading and immune-enhancing modes-of-action when the oncolytic adenovirus candidate was administered prior to immune checkpoint inhibition.
Corporate update including regulatory alignment with the FDA on proposed Phase 3 design, presentation of VIRAGE data at AACR, compassionate use dosing in retinoblastoma and financial results through March 31, 2026.
Peer-reviewed publications and conference presentations reporting Phase I and translational results for systemically administered oncolytic adenovirus candidates and related preclinical studies.